JP6118345B2 - 抗ホスホリパーゼｄ４抗体 - Google Patents

抗ホスホリパーゼｄ４抗体 Download PDF

Info

Publication number
JP6118345B2
JP6118345B2 JP2014554166A JP2014554166A JP6118345B2 JP 6118345 B2 JP6118345 B2 JP 6118345B2 JP 2014554166 A JP2014554166 A JP 2014554166A JP 2014554166 A JP2014554166 A JP 2014554166A JP 6118345 B2 JP6118345 B2 JP 6118345B2
Authority
JP
Japan
Prior art keywords
seq
antibody
pld4
sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014554166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508056A (ja
JP2015508056A5 (enExample
Inventor
民權 趙
民權 趙
智英 山崎
智英 山崎
まゆき 遠藤
まゆき 遠藤
晃司 石田
晃司 石田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6118345(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Priority to JP2014554166A priority Critical patent/JP6118345B2/ja
Publication of JP2015508056A publication Critical patent/JP2015508056A/ja
Publication of JP2015508056A5 publication Critical patent/JP2015508056A5/ja
Application granted granted Critical
Publication of JP6118345B2 publication Critical patent/JP6118345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014554166A 2012-01-31 2013-01-31 抗ホスホリパーゼｄ４抗体 Active JP6118345B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014554166A JP6118345B2 (ja) 2012-01-31 2013-01-31 抗ホスホリパーゼｄ４抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012018266 2012-01-31
JP2012018266 2012-01-31
JP2014554166A JP6118345B2 (ja) 2012-01-31 2013-01-31 抗ホスホリパーゼｄ４抗体
PCT/JP2013/052781 WO2013115410A2 (en) 2012-01-31 2013-01-31 Anti-phospholipase d4 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017058867A Division JP2017155045A (ja) 2012-01-31 2017-03-24 抗ホスホリパーゼｄ４抗体

Publications (3)

Publication Number Publication Date
JP2015508056A JP2015508056A (ja) 2015-03-16
JP2015508056A5 JP2015508056A5 (enExample) 2016-09-23
JP6118345B2 true JP6118345B2 (ja) 2017-04-19

Family

ID=47748721

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014554166A Active JP6118345B2 (ja) 2012-01-31 2013-01-31 抗ホスホリパーゼｄ４抗体
JP2017058867A Pending JP2017155045A (ja) 2012-01-31 2017-03-24 抗ホスホリパーゼｄ４抗体
JP2018220873A Active JP6830471B2 (ja) 2012-01-31 2018-11-27 抗ホスホリパーゼｄ４抗体
JP2020180164A Active JP7244102B2 (ja) 2012-01-31 2020-10-28 抗ホスホリパーゼｄ４抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017058867A Pending JP2017155045A (ja) 2012-01-31 2017-03-24 抗ホスホリパーゼｄ４抗体
JP2018220873A Active JP6830471B2 (ja) 2012-01-31 2018-11-27 抗ホスホリパーゼｄ４抗体
JP2020180164A Active JP7244102B2 (ja) 2012-01-31 2020-10-28 抗ホスホリパーゼｄ４抗体

Country Status (15)

Country Link
US (2) US9944715B2 (enExample)
EP (2) EP2809683B1 (enExample)
JP (4) JP6118345B2 (enExample)
KR (1) KR102098413B1 (enExample)
CN (2) CN112442128B (enExample)
AU (2) AU2013215886B2 (enExample)
CA (1) CA2863009C (enExample)
DK (2) DK2809683T3 (enExample)
ES (2) ES2694165T3 (enExample)
HU (2) HUE041552T2 (enExample)
IL (1) IL233794B (enExample)
PL (2) PL3431504T3 (enExample)
PT (1) PT2809683T (enExample)
TR (1) TR201819828T4 (enExample)
WO (1) WO2013115410A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
WO2015016386A1 (en) * 2013-07-30 2015-02-05 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase d4 antibody
BR112016014920A2 (pt) * 2013-12-24 2017-12-12 Astellas Pharma Inc novo anticorpo anti-bdca-2 humano
EP3402520A4 (en) 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
SG10202008769SA (en) * 2016-03-10 2020-10-29 Viela Bio Inc Ilt7 binding molecules and methods of using the same
CN105624325B (zh) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 肺腺癌的诊治标记物
ES2864013T3 (es) * 2017-10-14 2021-10-13 Abbvie Inc Conjugados de fármaco y anticuerpo activable anti-CD71 y métodos de uso de los mismos
CN110042123B (zh) * 2019-01-07 2023-01-17 西北农林科技大学 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法
WO2025085746A1 (en) * 2023-10-18 2025-04-24 Immunorx Pharma Inc. Humanized anti-s100a9 antibody
CN119120388A (zh) * 2024-10-22 2024-12-13 江苏亲科生物研究中心有限公司 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098015B2 (en) * 1999-06-11 2006-08-29 Millennium Pharmaceuticals, Inc. 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
CN1878795A (zh) 2002-12-02 2006-12-13 阿布格尼克斯公司 针对磷脂酶a2的抗体及其应用
JP4011100B2 (ja) * 2004-07-09 2007-11-21 中外製薬株式会社 抗グリピカン３抗体
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
WO2015016386A1 (en) * 2013-07-30 2015-02-05 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
JP7244102B2 (ja) 2023-03-22
PT2809683T (pt) 2019-01-17
CN112442128A (zh) 2021-03-05
WO2013115410A3 (en) 2013-09-26
PL3431504T3 (pl) 2021-10-18
HUE054362T2 (hu) 2021-09-28
IL233794B (en) 2021-04-29
IL233794A0 (en) 2014-09-30
JP2019048874A (ja) 2019-03-28
HUE041552T2 (hu) 2019-05-28
CN104284903A (zh) 2015-01-14
EP2809683B1 (en) 2018-10-03
BR112014018539A8 (pt) 2017-07-11
US10336834B2 (en) 2019-07-02
DK2809683T3 (en) 2018-12-10
CN104284903B (zh) 2020-10-09
JP2017155045A (ja) 2017-09-07
US9944715B2 (en) 2018-04-17
BR112014018539A2 (enExample) 2017-06-20
JP2015508056A (ja) 2015-03-16
DK3431504T3 (da) 2021-06-28
EP3431504B1 (en) 2021-03-24
ES2694165T3 (es) 2018-12-18
AU2013215886B2 (en) 2017-11-09
EP2809683A2 (en) 2014-12-10
AU2018200934A1 (en) 2018-03-01
CA2863009C (en) 2020-07-07
AU2013215886A1 (en) 2014-08-14
JP2021019630A (ja) 2021-02-18
CA2863009A1 (en) 2013-08-08
TR201819828T4 (tr) 2019-01-21
KR102098413B1 (ko) 2020-04-07
EP3431504A1 (en) 2019-01-23
US20180258185A1 (en) 2018-09-13
US20150044226A1 (en) 2015-02-12
KR20140126337A (ko) 2014-10-30
ES2873035T3 (es) 2021-11-03
AU2018200934B2 (en) 2019-09-12
CN112442128B (zh) 2024-05-17
JP6830471B2 (ja) 2021-02-17
PL2809683T3 (pl) 2019-03-29
WO2013115410A2 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
JP7244102B2 (ja) 抗ホスホリパーゼｄ４抗体
JP6412072B2 (ja) 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体
JP5420688B2 (ja) 抗ｉｌｔ７抗体
JP6843449B2 (ja) 抗ホスホリパーゼｄ４抗体を含む医薬
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170324

R150 Certificate of patent or registration of utility model

Ref document number: 6118345

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250